Using Long-Acting Somatostatin Analogue as Adjuvant Therapy for Post Resection Grade 2 Pancreatic Neuroendocrine Tumor: Interim Results from an Ongoing Multicenter Real-World Study in China

#2899

Introduction: Surgery was the preferred treatment in patients with resectable pancreatic neuroendocrine tumor (pNET), but recurrent lesion relapsed frequently within a short time. It was controversial whether patients with pNET need adjuvant therapy after surgery.

Aim(s): To investigate the effect of octreotide long-acting repeatable (LAR) as adjuvant therapy in patients with grade 2 pNET who received radical resection.

Materials and methods: This was a real-world study of 237 patients from 3 expert centers in China between 2008 and 2018, including 66 patients with at least 6 months of octreotide LAR adjuvant therapy (octreotide LAR group) and 171 patients without adjuvant therapy (control group). Patients were followed up after surgery. The primary end-point was DFS and OS.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Shi X

Authors: Shi X, Xu X, Zhang Y, Gao S, Li B,

Keywords: somatostatin analogue, adjuvant therapy, pancreatic neuroendocrine tumor,